Login to Your Account



Erbitux Misses In Pancreatic Cancer, Dropping ImClone

By Aaron Lorenzo


Wednesday, April 11, 2007
Shares in ImClone Systems Inc. took a 6.4 percent dip on word that Erbitux (cetuximab) missed the primary endpoint in a Phase III pancreatic cancer study, a backslide that follows a month of significant gains. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription